These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38570712)

  • 1. Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma.
    Wang S; Xiong Y; Luo Y; Shen Y; Zhang F; Lan H; Pang Y; Wang X; Li X; Zheng X; Lu X; Liu X; Cheng Y; Wu T; Dong Y; Lu Y; Cui J; Jia X; Yang S; Wang L; Wang Y
    EMBO Mol Med; 2024 May; 16(5):1115-1142. PubMed ID: 38570712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.
    Slee RB; Grimes BR; Bansal R; Gore J; Blackburn C; Brown L; Gasaway R; Jeong J; Victorino J; March KL; Colombo R; Herbert BS; Korc M
    Mol Cancer Ther; 2014 Feb; 13(2):307-315. PubMed ID: 24282275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo CRISPR screening identifies geranylgeranyl diphosphate as a pancreatic cancer tumor growth dependency.
    Kubota CS; Myers SL; Seppälä TT; Burkhart RA; Espenshade PJ
    Mol Metab; 2024 Jul; 85():101964. PubMed ID: 38823776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells.
    Bakke J; Wright WC; Zamora AE; Oladimeji P; Crawford JC; Brewer CT; Autry RJ; Evans WE; Thomas PG; Chen T
    BMC Cancer; 2019 Mar; 19(1):253. PubMed ID: 30898113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.
    Chang W; Liu M; Xu J; Fu H; Zhou B; Yuan T; Chen P
    Tumour Biol; 2016 Nov; 37(11):14813-14824. PubMed ID: 27638830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.
    Toledo CM; Ding Y; Hoellerbauer P; Davis RJ; Basom R; Girard EJ; Lee E; Corrin P; Hart T; Bolouri H; Davison J; Zhang Q; Hardcastle J; Aronow BJ; Plaisier CL; Baliga NS; Moffat J; Lin Q; Li XN; Nam DH; Lee J; Pollard SM; Zhu J; Delrow JJ; Clurman BE; Olson JM; Paddison PJ
    Cell Rep; 2015 Dec; 13(11):2425-2439. PubMed ID: 26673326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer.
    Gibori H; Eliyahu S; Krivitsky A; Ben-Shushan D; Epshtein Y; Tiram G; Blau R; Ofek P; Lee JS; Ruppin E; Landsman L; Barshack I; Golan T; Merquiol E; Blum G; Satchi-Fainaro R
    Nat Commun; 2018 Jan; 9(1):16. PubMed ID: 29295989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.
    Steinhart Z; Pavlovic Z; Chandrashekhar M; Hart T; Wang X; Zhang X; Robitaille M; Brown KR; Jaksani S; Overmeer R; Boj SF; Adams J; Pan J; Clevers H; Sidhu S; Moffat J; Angers S
    Nat Med; 2017 Jan; 23(1):60-68. PubMed ID: 27869803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.
    Mahajan UM; Teller S; Sendler M; Palankar R; van den Brandt C; Schwaiger T; Kühn JP; Ribback S; Glöckl G; Evert M; Weitschies W; Hosten N; Dombrowski F; Delcea M; Weiss FU; Lerch MM; Mayerle J
    Gut; 2016 Nov; 65(11):1838-1849. PubMed ID: 27196585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy.
    Zhang Z; Cheng L; Li J; Qiao Q; Karki A; Allison DB; Shaker N; Li K; Utturkar SM; Atallah Lanman NM; Rao X; Rychahou P; He D; Konieczny SF; Wang C; Shao Q; Evers BM; Liu X
    Cancer Res; 2022 Oct; 82(19):3532-3548. PubMed ID: 35950917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells.
    Du R; Sullivan DK; Azizian NG; Liu Y; Li Y
    BMC Cancer; 2021 Mar; 21(1):237. PubMed ID: 33676427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway.
    Zhang X; Xu J; Yan R; Zhang Y; Hu Z; Fu H; You Q; Cai Q; Yang D
    Aging (Albany NY); 2020 Apr; 12(8):6808-6822. PubMed ID: 32291380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
    Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
    Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
    BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
    Luna J; Boni J; Cuatrecasas M; Bofill-De Ros X; Núñez-Manchón E; Gironella M; Vaquero EC; Arbones ML; de la Luna S; Fillat C
    Gut; 2019 Aug; 68(8):1465-1476. PubMed ID: 30343272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
    Hu T; Shukla SK; Vernucci E; He C; Wang D; King RJ; Jha K; Siddhanta K; Mullen NJ; Attri KS; Murthy D; Chaika NV; Thakur R; Mulder SE; Pacheco CG; Fu X; High RR; Yu F; Lazenby A; Steegborn C; Lan P; Mehla K; Rotili D; Chaudhary S; Valente S; Tafani M; Mai A; Auwerx J; Verdin E; Tuveson D; Singh PK
    Gastroenterology; 2021 Nov; 161(5):1584-1600. PubMed ID: 34245764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53.
    Li J; Lama R; Galster SL; Inigo JR; Wu J; Chandra D; Chemler SR; Wang X
    Mol Cancer Ther; 2022 Apr; 21(4):535-545. PubMed ID: 35131878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.